Liquid biopsy in lung and breast cancer

Liquid biopsy is increasingly being adopted to support tumour profiling across cancer pathways, particularly where tissue is limited or results are needed quickly.

In this webinar, Pilar Ramos will provide an introduction to liquid biopsy comprehensive genomic profiling (CGP) and its role alongside tissue testing. Rachel Dodds will then share real‑world experience from Wales, including the integration of liquid biopsy into the lung cancer pathway and the use of ESR1 testing in blood samples from breast cancer patients.

Attendees will gain insights into where liquid biopsy adds value, challenges encountered during implementation, and how earlier molecular insights can support treatment decision‑making in routine clinical practice.

Learning objectives

• Understand the fundamentals of liquid biopsy comprehensive genomic profiling (CGP) and how it complements tissue testing.
• Learn where liquid biopsy provides clinical value, especially in lung and breast cancer pathways.
• See how earlier molecular insights can support faster, more informed treatment decision making in routine practice.
• Gain insights from real world implementation in Wales, including workflow integration and ESR1 testing in breast cancer.
• Recognize common operational and clinical challenges during liquid biopsy adoption—and strategies to overcome them.

Speakers

Rachel Dodds, PhD
Principal Clinical Scientist
All Wales Medical Genomics Service

Pilar Ramos, PhD
Sr Manager, Medical Affairs Europe
Illumina